Metagenomic next-generation sequencing for the diagnosis of fever of unknown origin in pediatric patients with hematological malignancy.

BACKGROUND AND AIMS: The aim of this study was to evaluate the performance of metagenomic next-generation sequencing (mNGS) in identifying microbiological etiologies in pediatric patients with hematological malignancies undergoing fever of unknown origin (FUO).

METHODS: A total of 147 children with hematological malignancy suffering febrile diseases without definite microbiological etiologies under conventional tests were enrolled. The clinical record, serum inflammatory biomarkers and mNGS results were analyzed.

RESULTS: At least one microorganism was identified by mNGS in 112 of 147 patients (76.2%). Two or more types of organisms were detected simultaneously in 35.7% (40/112) of samples. Of the 112 cases with positive mNGS results, the reported microorganisms were considered as etiologies of fever in 50 (44.6%) cases. The initial antimicrobial regimens were adjusted according to the mNGS results in 48 cases, with 41 patients' febrile diseases resolved. Totally, 27.9% (41/147) of patients benefit from mNGS. High IL-6 (>390pg/mL) level was associated with bacterial infection and could help to interpret the results of mNGS.

CONCLUSION: mNGS is a novel approach to determine the microbiological etiology of FUO in hematological malignancy patients, which benefit about a quarter of all patients tested. Integration of IL-6 can improve the diagnostic precision of bacterial infection.